Deep Brain Stimulation Devices Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019
Albany, New York (PRWEB) May 16, 2014 -- A rise in ageing population has been found to be the major causative factor for development of Parkinson’s disease. Parkinson’s disease is the second-most common chronic and progressive neurodegenerative disorder featuring the cardinal symptoms of postural instability, bradykinesia, akinesia and tremors due to loss of dopamine producing neurons in substantia nigra of the mid-brain. The mean age of onset of Parkinson’s disease is 55 to 60 years. According to the Parkinson’s Disease Foundation (PDF), approximately 10 million people are estimated to currently live with Parkinson’s disease globally.
See more details with TOC: http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html.
There are multiple treatment options available in the market to treat patients living with Parkinson’s disease. These include chemotherapy, stem cell therapy, physical therapy and surgical treatment. Among drug therapies, the most potent medication is levodopa/Carbidopa therapy. Other drugs used to treat PD are dopamine agonists, anti-cholinergic, MAO-B inhibitors and Catechol-O-Methyltransferase (COMT) inhibitors. However, after long term chemotherapy treatment, the drugs used lose their effectiveness. In the advance stages of Parkinson’s disease surgical intervention becomes imperative. DBS as a surgical intervention is considered to be highly effective and safe as compared to open surgeries such as thalamotomy, pallidotomy and subthalamotomy.
Technological advances have aided the growth of this market. Recently, a research team from the Tel Aviv University has been working on an advanced biometric computer chip implant known as Rehabilitation Nano Chip (ReNaChip) that would support healthcare professionals and neurosurgeons in restoring normal brain functions. The innovative ReNaChip would significantly enhance the existing technology known as DBS by delivering electrical stimulation to the appropriate brain area. In addition, companies such as Boston Scientific has recently introduced its flagship product named “Vercise DBS”. This product is expected to enhance the battery life of the device by 25 years thus competing on pricing with replaceable battery providers for DBS that lasts just for 5 years. Furthermore, an independent unique MICC technology (Multiple Independent Current Control) has been incorporated in Vercise DBS system to control the side-effects of stimulation by controlling the current level at each individual contact on the lead.
Get free report sample: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1435.
Leading players such as Medtronic and St. Jude Medical are continuously investing in research and development to increase the applicability of DBS devices in treating various movement disorders. Currently, the DBS procedure entails implantation of two leads for bilateral stimulation; however, research is currently being carried out to implant multiple lead array systems to stimulate various sites in brain. Thus, the three major players of this market i.e. Medtronic, Boston Scientific and St. Jude have created a strong entry barrier for new entrants and dominate the market. However, few new entrants such as Sapiens Neuro and Aleva Neurotherapeutics SA are expected to launch their new products in next few years, which are currently under clinical trials for treatment of Parkinson’s.
See more details with TOC: http://www.transparencymarketresearch.com/deep-brain-stimulator-market.html.
Sheela AK, Transparency Market Research, http://www.transparencymarketresearch.com, +1 (518) 618-1030, [email protected]
Share this article